Clinical Trial Update: Universal 4SCAR7U Targeting CD7-positive Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating Universal 4SCAR7U, a CD7-targeting therapy from Shenzhen Geno-Immune Medical Institute, is currently recruiting. The study includes T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Natural Killer Cell Lymphoma
• T-cell Acute Lymphoblastic Leukemia
• T-cell Acute Lymphoblastic Lymphoma

Drugs mentioned

• 4SCAR7U

Snippet

Sponsor: Shenzhen Geno-Immune Medical Institute | Conditions: T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma | Phase 1 | Status: RECRUITING